Development of a Screening Tool to Detect and Stage Cachectic Cancer Patients

Universitaire Ziekenhuizen KU Leuven

Status: Completed

Conditions: Cachexia

Study type: Observational

Funder types: Other

Identifiers

NCT01533909

S54035

Details and patient eligibility

About

The aim of the study is to develop a screenings tool that will enable hospital nurses to detect and stage cancer cachectic patients. The early detection and staging of cancer cachexia will assist the oncology team in providing the cachectic cancer patient tailor-made patient care.

Full description

In this cross-sectional study, the participants will complete 4 times a set of questionnaires and measurements. The data that will be collected is:

age; sex; height; weight; type of tumour; classification of malignant tumours (TNM); progression of tumour and used therapy; blood sample to analyse albumin, creatine, hemoglobin, LDH and CRP; use of parental nutrition; dietary assessment; use of nutritional supplements; Quality of Life by using the EORTC-QlQ; Subjective Global Assessment; presence of Percutaneous endoscopic gastrostomy; use of enteral or parenteral nutrition; body composition based on a Bio Impedance Assessment; hand grip strength and mid upper arm circumference. Based on all these data points a easy to use tool/score for a hospital setting will be created. During the first assessment the measurements will be done in the morning and the evening to test the reproducibility.

Enrollment: 56 patients

Sex: All

Ages: 18 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• New Diagnosed Patients With Primary Head and Neck Cancer Neoplasms
• New Diagnosed Patients With Metastatic Pancreatic Neoplasms
• New Diagnosed Patients With Metastatic Colonic Neoplasms

Exclusion criteria

• Patients With Other Primary Neoplasms
• Patients Already in Therapy
• Patients With Non-metastatic Colonic or Pancreatic Neoplasms

Trial design

56 participants in 1 patient group

Cancer patients

Description:

As this is not an intervention study there is only one cohort. Patients that will be included and excluded are described in the eligibility section.